Impact of statistical models on the prediction of type 2 diabetes using non-targeted metabolomics profiling
Froguel, PhilippeNote: Order does not necessarily reflect citation order of authors.
MetadataShow full item record
CitationYengo, L., A. Arredouani, M. Marre, R. Roussel, M. Vaxillaire, M. Falchi, A. Haoudi, et al. 2016. “Impact of statistical models on the prediction of type 2 diabetes using non-targeted metabolomics profiling.” Molecular Metabolism 5 (10): 918-925. doi:10.1016/j.molmet.2016.08.011. http://dx.doi.org/10.1016/j.molmet.2016.08.011.
AbstractObjective: Characterizing specific metabolites in sub-clinical phases preceding the onset of type 2 diabetes to enable efficient preventive and personalized interventions. Research design and methods We developed predictive models of type 2 diabetes using two strategies. One strategy focused on the probability of incidence only and was based on logistic regression (MRS1); the other strategy accounted for the age at diagnosis of diabetes and was based on Cox regression (MRS2). We assessed 293 metabolites using non-targeted metabolomics in fasting plasma samples of 1,044 participants (including 231 incident cases over 9 years) used as training population; and fasting serum samples of 128 participants (64 incident cases versus 64 controls) used as validation population. We applied a LASSO-based variable selection aiming at maximizing the out-of-sample area under the receiver operating characteristic curve (AROC) and integrated AROC. Results: Sixteen and 17 metabolites were selected for MRS1 and MRS2, respectively, with AROC = 90% and 73% in the training and validation populations, respectively for MRS1. MRS2 had a similar performance and was significantly associated with a younger age of onset of type 2 diabetes (β = −3.44 years per MRS2 SD in the training population, p = 1.56 × 10−7; β = −4.73 years per MRS2 SD in the validation population, p = 4.04 × 10−3). Conclusions: Overall, this study illustrates that metabolomics improves prediction of type 2 diabetes incidence of 4.5% on top of known clinical and biological markers, reaching 90% in total AROC, which is considered the threshold for clinical validity, suggesting it may be used in targeting interventions to prevent type 2 diabetes.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:29407756
- HMS Scholarly Articles